RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.

RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.

Add to Collection
2011 Feb 10 Others Fist_Author_Year_PM

Full Author : ['Singh, Shuchita', 'Roy, Subhasis', 'Sethi, Sachin', 'Benjamin, Biju', 'Sundaram, Sindhuja', 'Khanna, Vivek', 'Kandalkar, Sachin R', 'Pal, Chanchal', 'Kant, Rajiv', 'Patra, Ashok Kumar', 'Rayasam, Geetavani', 'Mittra, Shivani', 'Saini, Kulvinder Singh', 'Paliwal, Jyoti', 'Chugh, Anita', 'Ahmed, Shahadat', 'Sattigeri, Jitendra', 'Cliff, Ian', 'Ray, Abhijit', 'Bansal, Vinay S', 'Bhatnagar, Pradip Kumar', 'Davis, Joseph Alex']
Journal Title : European journal of pharmacology
Chapter : Section3
Journal Year : 2011
Cited by : Not Available

Dipeptidyl peptidase IV (DPP-IV) inhibiton is a well recognized approach to treat Type 2 diabetes. RBx-0597 is a novel DPP-IV inhibitor discovered in our laboratory. The aim of the present study was to characterize the pharmacological profiles of RBx-0597.....

Keywords : ["type diabetes", "slowbinding inhibitor", "potent selective", "dipeptidyl peptidaseiv", "treatment"]